Author

Yao Yu

Observed name: Y. Yu

Institution: Seagen (United States)

Observed institution: Seagen (United States)

OpenAlex ID: A5028797544

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

2022 · Christopher J. Hoimes, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 286

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

2023 · Peter H. O'Donnell, Matthew I. Milowsky, et al. · Journal of Clinical Oncology · 196

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

2022 · J.E. Rosenberg, M. Milowsky, et al. · Annals of Oncology · 39

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

2024 · Matthew I. Milowsky, Peter H. O'Donnell, et al. · Journal of Clinical Oncology · 22

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

2023 · Shilpa Gupta, Jonathan E. Rosenberg, et al. · Journal of Clinical Oncology · 22

Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.

2023 · Matthew I. Milowsky, Peter H. O'Donnell, et al. · Journal of Clinical Oncology · 22

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.

2023 · Thomas W. Flaig, Jonathan E. Rosenberg, et al. · Journal of Clinical Oncology · 17

2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

2023 · S. Sridhar, P.H. O'Donnell, et al. · Annals of Oncology · 12

Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.

2023 · Peter H. O'Donnell, Jonathan E. Rosenberg, et al. · Journal of Clinical Oncology · 10

Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.

2023 · Ashish M. Kamat, Gary D. Steinberg, et al. · Journal of Clinical Oncology · 8

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.

2022 · Daniel P. Petrylak, Thomas W. Flaig, et al. · Journal of Clinical Oncology · 6

A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab

2023 · Christopher J Hoimes, Thomas W Flaig, et al. · Future Oncology · 3

Works count: 12

Citation count: 643

H-index: 9

I10-index: 9